A 64-year-old woman, without relevant comorbidities, operated on for a right breast cancer by means of an extended lumpectomy and selective sentinel lymph node biopsy, with the following anatomopathological result: Infiltrating ductal carcinoma poorly dlferentiated (grade 3), size 2.2 cm (pT2), estrogen and progesterone receptor positive, Ki67 25%, HER2 negative. There is macroscopic involvement of the sentinel lymph node, although there is no involvement of the rest of the isolated axillary nodes (pN1). What adjuvant systemic treatment do you consider most appropriate for this patient?
It is a Luminal B. According to the SEGO, this patient is a candidate for chemotherapy treatment because of the high histologic grade and high tumor proliferation.
Adjuvant hormone therapy including aromatase inhibitors.
Adjuvant chemotherapy, preferably with anthracyclines and taxanes, followed by hormone therapy.
Adjuvant chemotherapy in association with the monoclonal antibody trastuzumab, followed by hormone therapy.
Adjuvant chemotherapy, preferably with anthracyclines and taxanes.
It is a Luminal B. According to the SEGO, this patient is a candidate for chemotherapy treatment because of the high histologic grade and high tumor proliferation.